Scanning mutagenesis of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor

Journal of Physiology Paris

Volumn 92, Issue 3-4, 1998, Pages 269-274

  Hulme, Edward C ^a   Lu, Zhi Liang ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; GUANINE NUCLEOTIDE BINDING PROTEIN; METHYLSCOPOLAMINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINYL BENZILATE; TRITIUM;

ANIMAL CELL; CELL STRAIN; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; MUTAGENESIS; NONHUMAN; PROTEIN DOMAIN;

EID: 0032105388     PISSN: 09284257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4257(98)80031-4     Document Type: Conference Paper

References (15)

1. [1] Baldwin J.M., The probable arrangement of the helices in G protein-coupled receptors, EMBO J. 12 (1993) 1693-1703.
2. [2] Baldwin J.M., Schertler G.F.X., Unger V.M., An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors, J. Mol. Biol. 272 (1997) 144-164.
3. [3] Berrie C.P., Birdsall N.J.M., Hulme E.C., Keen M., Stockton J.M., Solubilization and characterization of guanine nucleotide-sensitive muscarinic agonist binding sites from rat myocardium, Br. J. Pharmacol. 82 (1984) 853-861.
4. [4] Black J.W., Leff P., Operational models of pharmacological agonism, Proc. Roy. Soc. Lond. B. 220 (1983) 141-162.
5. [5] Clackson T., Wells J.A., A hot spot of binding energy in a hormone-receptor interface, Science 267 (1995) 383-386.
6. [6] Farrens D.L., Altenbach C., Yang K., Khorana H.G., Requirement of rigid-body motion of transmembrane helices for light-activation of rhodopsin, Science 274 (1996) 768-770.
7. [7] Javitch J.A., Fu D., Chen J., Karlin A., Mapping the binding site crevice of the dopamine D2 receptor by the substituted cysteine accessibility method, Neuron 14 (1995) 825-831.
8. [8] Jones P.G., Curtis C.A.M., Hulme E.C., The function of a highly-conserved arginine residue in activation of the muscarinic M1 receptor. Eur. J. Pharmacol. 288, 251-257.
9. [9] Kurtenbach E., Curtis C.A.M., Pedder E.K., Aitken A., Harris A.C.M., Hulme E.C., Muscarinic acetylcholine receptors: Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation, J. Biol. Chem. 265 (1990) 13702-13708.
10. [10] Lu Z.L., Curtis C.A., Jones P.G., Pavia J., Hulme E.C., The role of the aspartate-arginine-tyrosine triad in the M1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signalling, Mol. Pharmacol. 51 (1997) 234-241.
11. [11] Page K.M., Curtis C.A.M., Jones P.G., Hulme E.C., The functional role of the binding site aspartate in muscarinic acetylcholine receptors probed by site-directed mutagenesis, Eur. J. Pharmacol. 289 (1995) 429-437.
12. [12] Samama P., Cotecchia S., Costa T., Lefkowitz R.J., A mutation-induced activated state of the β2-adrenergic receptor: Extending the ternary complex model, J. Biol. Chem. 268 (1993) 4625-4636.
13. [13] Spalding T.A., Birdsall N.J.M., Curtis C.A.M., Hulme E.C., Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors, J. Biol. Chem. 269 (1994) 4092-4097.
14. [14] Ward W.H.J., Timms D., Fersht A.R., Protein engineering and the study of structure-function relationships in receptors, TIPS 11 (1990) 280-284.
15. [15] Wess J., Molecular biology of muscarinic acetylcholine receptors, Crit. Rev. Neurobiol. 10 (1996) 69-99.